Kidney International Reports最新文献

{"title":"Efficacy and Safety of Telitacicept as an Add-On Therapy for Refractory Immunoglobulin A Nephropathy or Immunoglobulin A Vasculitis Nephropathy in Children","authors":"Jiaojiao Liu , Xinli Han , Xiaoyun Jiang , Xia Gao , Guomin Li , Xiaoyan Fang , Jing Chen , Yihui Zhai , Jialu Liu , Yuxin Pei , Jiayi Zhang , Guoqin Zhu , Qian Shen , Hong Xu","doi":"10.1016/j.ekir.2024.11.1363","DOIUrl":"10.1016/j.ekir.2024.11.1363","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 940-943"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation","authors":"Dominique Bertrand ,&nbsp;Arnaud Del Bello ,&nbsp;Rebecca Sberro Soussan ,&nbsp;Sophie Caillard ,&nbsp;Guillaume Claisse ,&nbsp;Lionel Couzi ,&nbsp;Sophie Girerd ,&nbsp;Alexandre Hertig ,&nbsp;Yannick Le Meur ,&nbsp;Vincent Pernin ,&nbsp;Coralie Poulain ,&nbsp;Cédric Rafat ,&nbsp;Marie Matignon ,&nbsp;Arnaud Buteux ,&nbsp;Arnaud François ,&nbsp;Mathilde Lemoine ,&nbsp;Charlotte Laurent ,&nbsp;Nassim Kamar ,&nbsp;Tristan de Nattes ,&nbsp;Dominique Guerrot","doi":"10.1016/j.ekir.2024.12.031","DOIUrl":"10.1016/j.ekir.2024.12.031","url":null,"abstract":"<div><h3>Introduction</h3><div>Although long-term graft survival is comparable with that of ABO-compatible (ABOc) renal transplantation, the risk of antibody-mediated rejection (ABMR) following ABO-incompatible (ABOi) transplantation is higher and can occur as an early thrombotic microangiopathy (TMA).</div></div><div><h3>Methods</h3><div>We designed a retrospective multicenter study, including all patients who presented with a TMA (histological and/or biological) after an ABOi transplantation (&lt; 1 month) and compared with matched controls who had a favorable initial course with a normal biopsy.</div></div><div><h3>Results</h3><div>Between 2013 and 2022, 375 ABOi kidney transplants were performed and 23 patients (6.1%) developed TMA (median: 1 day, interquartile range [IQR]: 0–3 days). Twenty-one patients (91.3%) had biological TMA. Among 23 early graft biopsies, histological evidence of active TMA was found in 17 cases (80.9%). All patients received treatment: 20 of 23 received at least 1 session of plasmapheresis and 19 of 23 received at least 1 injection of eculizumab. Eight early graft losses (30.4%) occurred (median: 7 days, IQR: 3–16 days). IgG and IgM anti–blood group antibody (ABGA) levels (peak and last pregraft assay) were significantly higher in the TMA group (peak: <em>P</em> = 0.01 for IgG and <em>P</em> = 0.0006 for IgM; last assay before kidney transplantation [KT]: <em>P</em> &lt; 0.0001 for IgG and <em>P</em> = 0.0003 for IgM). A level ≥ 1/8 for IgG and ≥ 1/4 or IgM before transplantation were significantly and independently predictive of the occurrence of TMA. No other predictive factors were found.</div></div><div><h3>Conclusion</h3><div>TMA after ABOi transplantation is not a rare phenomenon and is associated with a poor prognosis in nonresponders-to-treatment patients. ABGA titer performed by hemagglutination is an imperfect marker of the occurrence of such a phenomenon.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 828-837"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Study of Diagnostic Performances of Vascular Biomarkers Soluble fms-Like Tyrosine Kinase and Placental Growth Factor in Scleroderma Renal Crisis","authors":"Aïcha Kante ,&nbsp;Paul Legendre ,&nbsp;Bérangère S. Joly ,&nbsp;Bertrand Dunogué ,&nbsp;Alexandre Hertig ,&nbsp;Benjamin Terrier ,&nbsp;Elodie Massolin ,&nbsp;Paul Coppo ,&nbsp;Felix Ackermann ,&nbsp;Giorgina Barbara Piccoli ,&nbsp;Luc Mouthon ,&nbsp;Jean Guibourdenche ,&nbsp;Benjamin Chaigne","doi":"10.1016/j.ekir.2024.12.025","DOIUrl":"10.1016/j.ekir.2024.12.025","url":null,"abstract":"<div><h3>Introduction</h3><div>Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. In this retrospective study, we evaluated the potential prognostic and diagnostic roles of angiogenesis molecules, placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1) and sFlt1/PlGF ratio as biomarkers in SRC.</div></div><div><h3>Methods</h3><div>Sera samples from 27 patients with a history of SRC (SSc-SRC+) were collected following event occurence. Biomarker levels were assessed using an electrochemiluminescence immunoassay and compared with age- and sex-matched patients with SSc-SRC− (<em>n</em> = 24), hemolytic uremic syndrome (HUS) (<em>n</em> = 27), malignant hypertension (MHT) (<em>n</em> = 22), and donors (<em>n</em> = 61). Areas under the receiver-operating-characteristic curves (AUC) were used to evaluate diagnostic accuracy. Long-term dialysis risk was evaluated using a Cox model.</div></div><div><h3>Results</h3><div>The median (interquartile range [IQR]) PlGF (pg/ml) was significantly higher in the serum of patients with SSc-SRC+ (42.1 [21.4–51.8]) compared with donors (14.7 [11.8–17.9]), those with SSc-SRC− (18.5 [14.7–21.5]) (<em>P</em> &lt; 0.0001), those with HUS (22.8 [19.5–29.6]), and those with MHT (25.5 [17.2–39.3]) (<em>P</em> &lt; 0.0001). In a multivariate regression adjusting for multiple confounders, PlGF was associated with higher SRC risk with an odds ratio of 1.08 [1.01–1.22], (<em>P</em> = 0.034). A PlGF level above 24.5 pg/ml revealed an AUC of 0.81 (confidence interval [0.68–0.94]), a specificity of 95%, and a sensitivity of 67% for SRC diagnosis. Eleven patients with SSc-SRC+ reached end-stage kidney failure with significantly higher PlGF (42.9 [22.4–78.2]) compared with patients who were dialysis-free (19.7 [15.6–29.7], <em>P</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>Serum PlGF may identify the risk of SRC occurrence among patients with SSc with a good specificity and represents a potential tool for long-term dialysis risk evaluation.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 866-876"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Mitochondrial AKT1 Signaling in Renal Tubular Injury of Metabolic Syndrome","authors":"Hugo Y.-H. Lin ,&nbsp;I-Ya Chen ,&nbsp;Tzu-Ming Wang ,&nbsp;Chia-Hung Yen ,&nbsp;Yumay Chen ,&nbsp;Yen-Hua Chen ,&nbsp;Dao-Fu Dai ,&nbsp;Jee-Fu Huang ,&nbsp;Yi-Wen Chiu ,&nbsp;Ming-Yu Yang","doi":"10.1016/j.ekir.2024.12.021","DOIUrl":"10.1016/j.ekir.2024.12.021","url":null,"abstract":"<div><h3>Introduction</h3><div>Metabolic syndrome (MetS) is increasingly recognized as a contributor to kidney disease, yet the underlying mechanisms remain poorly defined. Recent studies suggest a pivotal role for mitochondrial dysfunction in renal injury. We hypothesized that mitochondrial AKT1 signaling in renal tubules plays a critical role in MetS-related kidney injuries.</div></div><div><h3>Methods</h3><div>MetS was induced in a 8-week-old C57BL/6 male mice using a high-fat diet (HFD) for 4 months compared with controls on a standard chow diet. Additional experiments were conducted in DB/DB diabetic mice and their controls (WT and DB/WT) to validate findings. Renal metabolic parameters, mitochondrial AKT1 signaling, and markers of kidney injury were assessed.</div></div><div><h3>Results</h3><div>MetS mice exhibited significant weight gain, altered glucose handling, and decreased energy expenditure. Although kidney size and basic renal function (blood urea nitrogen [BUN], creatinine) were unchanged, markers of renal damage, including proteinuria (<em>P</em> = 0.0002) and KIM-1 (<em>P</em> &lt; 0.0001) were elevated. Histological analyses showed increased tubular injury (<em>P</em> &lt; 0.0001) and glomerulosclerosis (<em>P</em> = 0.0004). Transmission electron microscopy revealed aberrant mitochondria (<em>P</em> &lt; 0.001), with reduced cristae length (<em>P</em> = 0.012) and numbers (<em>P</em> &lt; 0.001). Immunohistochemistry, immunofluorescence, and Western blot analysis confirmed increased phosphorylated AKT1 (pAKT1) in the mitochondria of renal tubules (<em>P</em> = 0.0474), findings corroborated in DB/DB mice. This translocation of pAKT1 into mitochondria correlated with decreased cell viability upon inhibition of heat shock protein 90, indicating a dependency on mitochondrial AKT1 for cell survival.</div></div><div><h3>Conclusion</h3><div>These findings underscore the mechanistic link between mitochondrial AKT1 signaling and renal tubular injury in MetS. Targeting mitochondrial dysfunction may offer new avenues for preventing and treating kidney diseases in patients with MetS.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 906-920"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression of HIV-1 CKDs: Viral Load Versus APOL1 Risk Alleles","authors":"Patricio E. Ray","doi":"10.1016/j.ekir.2025.01.005","DOIUrl":"10.1016/j.ekir.2025.01.005","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 657-659"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Pressure Goals and Outcomes in Kidney Transplant Recipients in an Analysis of the Collaborative Transplant Study","authors":"Claudius Speer ,&nbsp;Louise Benning ,&nbsp;Christian Morath ,&nbsp;Martin Zeier ,&nbsp;Norbert Frey ,&nbsp;Gerhard Opelz ,&nbsp;Bernd Döhler ,&nbsp;Thuong Hien Tran ,&nbsp;Collaborative Transplant Study","doi":"10.1016/j.ekir.2024.12.004","DOIUrl":"10.1016/j.ekir.2024.12.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Hypertension is an independent risk factor for cardiovascular disease, the leading cause of death in kidney transplant recipients. However, optimal blood pressure targets posttransplant remain uncertain. We investigated the impact of different American College of Cardiology and the American Heart Association (ACC/AHA) blood pressure categories on graft survival and patient mortality, and analyzed subgroup-specific effects.</div></div><div><h3>Methods</h3><div>This large-scale retrospective study included 1-year blood pressure data from 62,556 kidney transplant recipients across 209 centers in 39 countries, using the collaborative transplant study (CTS) database. Primary outcomes were death-censored graft failure and patient mortality during first 6 years posttransplantation. Multivariable Cox regression analysis controlled for multiple immunological and nonimmunological confounders.</div></div><div><h3>Results</h3><div>At 1 year posttransplant, 77% of kidney transplant recipients had hypertension. We did not find a significant difference in death-censored graft failure and patient mortality between patients with normal blood pressure (&lt; 120/&lt; 80 mm Hg) and those with elevated blood pressure (120–129/&lt; 80 mm Hg). Hypertension stages 1 (130–139/80–89 mm Hg) and 2 (≥ 140/≥ 90 mm Hg) were associated with an 11% and 55% increased risk of death-censored graft failure, respectively. Patient mortality was only significantly increased in those with hypertension stage 2. Kidney transplant recipients with hypertension stage 2 continued to have an increased risk of graft failure, even when they achieved normal blood pressure in the second year posttransplant. Certain subgroups of patients were at particularly high risk of detrimental effects of high blood pressure.</div></div><div><h3>Conclusion</h3><div>This study highlights the negative impact of hypertension early after kidney transplantation and emphasizes the importance of effective treatment to improve long-term graft and patient survival.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 780-790"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial Dysfunction: The Nexus of Aging, Dyslipidemia, and CKD","authors":"Yu-Hsiang Lin ,&nbsp;Kuo-Jen Lin ,&nbsp;Chih-Hsiang Chang","doi":"10.1016/j.ekir.2025.01.010","DOIUrl":"10.1016/j.ekir.2025.01.010","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 973-974"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Long-Term Outcomes in Cystinosis With Comprehensive Patient-Centered Care","authors":"Ewa Elenberg","doi":"10.1016/j.ekir.2024.10.038","DOIUrl":"10.1016/j.ekir.2024.10.038","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages S775-S778"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Avoid Preanalytical Errors When Using Urine Biomarkers of Exposure” [Kidney International Reports Volume 10, Issue 1, January 2025, Page 281]","authors":"Kristina Jakobsson ,&nbsp;Antonio d’Errico ,&nbsp;Hans Kromhout ,&nbsp;Christian Lindh ,&nbsp;Thomas Lundh ,&nbsp;Esteban Arias Monge ,&nbsp;Sandra Peraza ,&nbsp;David Wegman ,&nbsp;Ineke Wesseling","doi":"10.1016/j.ekir.2025.01.001","DOIUrl":"10.1016/j.ekir.2025.01.001","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Page 977"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies","authors":"Maxime Teisseyre ,&nbsp;Marco Allinovi ,&nbsp;Vincent Audard ,&nbsp;Marion Cremoni ,&nbsp;Giulia Belvederi ,&nbsp;Alexandre Karamé ,&nbsp;Matteo Accinno ,&nbsp;Julien Duquesne ,&nbsp;Vinod Sharma ,&nbsp;Céline Fernandez ,&nbsp;Kévin Zorzi ,&nbsp;Mounir El Maï ,&nbsp;Vesna Brglez ,&nbsp;Sylvia Benzaken ,&nbsp;Vincent L.M. Esnault ,&nbsp;Alessandra Vultaggio ,&nbsp;Harbir Singh Kohli ,&nbsp;Raja Ramachandran ,&nbsp;Calogero Lino Cirami ,&nbsp;Barbara Seitz-Polski","doi":"10.1016/j.ekir.2024.12.012","DOIUrl":"10.1016/j.ekir.2024.12.012","url":null,"abstract":"<div><h3>Introduction</h3><div>Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur. One mechanism of resistance is the occurrence of antidrug antibodies. Obinutuzumab and ofatumumab are humanized and human monoclonal antibodies, respectively, that target B cells. These treatments have been shown to be effective in membranous nephropathy. However, obinutuzumab and ofatumumab have never been compared with rituximab in the treatment of patients with membranous nephropathy with anti-rituximab antibodies. We aimed to compare the efficacy and safety of obinutuzumab and ofatumumab with rituximab in patients with membranous nephropathy with anti-rituximab antibodies.</div></div><div><h3>Methods</h3><div>This international retrospective multicenter study enrolled 34 patients with membranous nephropathy from 5 nephrology departments in France, India, and Italy. All the patients had previously developed anti-rituximab antibodies. Nineteen patients received rituximab, 12 received obinutuzumab, and 3 received ofatumumab.</div></div><div><h3>Results</h3><div>Patients treated with obinutuzumab or ofatumumab were more likely to achieve clinical remission than those treated with rituximab at month 6 (87% vs. 37%, <em>P</em> = 0.005) and month 12 (87% vs. 42%, <em>P</em> = 0.01). Patients treated with obinutuzumab or ofatumumab were more likely to achieve immunological remission and B-cell depletion at month 6 than the patients treated with rituximab (92% vs. 56%, <em>P</em> = 0.04 and 93% vs. 35%, <em>P</em> = 0.002, respectively). No serious adverse events were reported in the obinutuzumab or ofatumumab group.</div></div><div><h3>Conclusion</h3><div>Obinutuzumab and ofatumumab are more effective than rituximab in treating patients with membranous nephropathy with anti-rituximab antibodies. Anti-rituximab antibodies should be systematically monitored, to determine appropriate treatment.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 753-761"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}